S*BIO CEO Jan-Anders Karlsson On Development Success In Singapore: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Founded in 2000 as a joint venture between Chiron and the Economic Development Board of Singapore, S*BIO was one of the first biotech companies in Singapore. The company's pipeline consists of novel targeted small molecule drugs for the treatment of cancer with leading programs around histonedeacetylases and kinases. S*BIO announced Oct. 20 completion of a $26 million Series-B financing led by Bio*One Capital and Aravis Venture, which will allow the company to more forward into Phase II clinical development of its two lead oncology compounds. S*BIO CEO Jan-Anders Karlsson recently sat down with PharmAsia News' Australia bureau to discuss its pipeline and operations out of Singapore.
You may also be interested in...
Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara
The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.
Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara
PERTH, Australia - Just two weeks after announcing a development collaboration deal with Onyx Pharmaceuticals on JAK2 inhibitors, Singapore-based S*BIO announced it inked a licensing deal Jan. 21 with San Diego-based Tragara Pharmaceuticals covering its multi-kinase inhibitor SB1317 for leukemia
Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara
The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.